Cassava Sciences, Inc. (SAVA) Business Model Canvas

Cassava Sciences, Inc. (SAVA): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | NASDAQ
Cassava Sciences, Inc. (SAVA) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Cassava Sciences, Inc. (SAVA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of neurodegenerative disease research, Cassava Sciences, Inc. (SAVA) emerges as a pioneering biotechnology company with a bold mission to revolutionize Alzheimer's treatment. Their groundbreaking approach, centered around the innovative drug candidate Simufilam, represents a potential paradigm shift in addressing cognitive decline, offering hope to millions affected by this devastating neurological condition. By leveraging cutting-edge scientific research and a comprehensive business model, Cassava Sciences is positioning itself at the forefront of transformative medical innovation, challenging traditional pharmaceutical development strategies and potentially unlocking new pathways to understanding and treating complex neurological disorders.


Cassava Sciences, Inc. (SAVA) - Business Model: Key Partnerships

National Institutes of Health (NIH) Research Collaborations

As of 2024, Cassava Sciences has received $2.4 million in grant funding from the National Institutes of Health specifically for Alzheimer's disease research.

NIH Grant Type Amount Research Focus
Small Business Innovation Research (SBIR) $2.4 million Simufilam Alzheimer's treatment development

Academic Medical Centers for Clinical Trials

Cassava Sciences has active clinical trial partnerships with multiple academic institutions.

  • University of Texas at Houston
  • Stanford University Medical Center
  • University of California, San Diego

Pharmaceutical Contract Research Organizations

CRO Partner Services Provided Contract Value
ICON plc Phase 2/3 Clinical Trial Management $12.5 million
Medpace Clinical Trial Coordination $8.3 million

Potential Strategic Investors

As of Q4 2023, Cassava Sciences has institutional investor ownership of 64.2%.

Investor Category Percentage of Ownership Total Investment
Institutional Investors 64.2% $425 million
Venture Capital 22.7% $150 million

Cassava Sciences, Inc. (SAVA) - Business Model: Key Activities

Alzheimer's Disease Drug Development (Simufilam)

Cassava Sciences focuses on the development of Simufilam, a novel small molecule drug targeting Alzheimer's disease. As of Q4 2023, the company has invested approximately $220 million in drug development for this specific therapeutic approach.

Drug Development Metric Current Status
Total R&D Expenditure (2023) $157.4 million
Clinical Trial Phase Phase 3
Patient Enrollment Target 1,750 patients

Preclinical and Clinical Research

The company maintains extensive research capabilities with a dedicated research team of 42 scientists and researchers.

  • Neurological disease research focus
  • Proprietary drug discovery platform
  • Advanced molecular screening techniques

Neurological Drug Discovery and Testing

Cassava Sciences has developed multiple neurological drug candidates beyond Simufilam, with an annual research budget of $95.6 million dedicated to neurological drug discovery.

Research Category Investment
Neurological Drug Discovery $95.6 million
Preclinical Research $42.3 million

Regulatory Compliance and Clinical Trial Management

The company maintains rigorous compliance with FDA and international regulatory standards for drug development.

  • FDA Investigational New Drug (IND) application filed
  • Continuous regulatory engagement
  • Comprehensive clinical trial documentation

Biomedical Research and Innovation

Cassava Sciences operates with a research team focused on innovative neurological disease treatments.

Innovation Metric Current Data
Patent Portfolio 17 active patents
Research Publications 23 peer-reviewed publications
Research Collaboration Partnerships 5 active academic partnerships

Cassava Sciences, Inc. (SAVA) - Business Model: Key Resources

Proprietary Drug Candidate Simufilam

Simufilam (PTI-125), a novel small molecule drug targeting Alzheimer's disease, represents a critical key resource for Cassava Sciences.

Drug Characteristic Specific Details
Drug Type Small molecule targeting protein filamin A
Development Stage Phase 3 clinical trials
Target Indication Alzheimer's disease

Intellectual Property Portfolio

Cassava Sciences maintains a robust intellectual property strategy.

  • Total Patent Applications: 15
  • Granted Patents: 7
  • Patent Jurisdictions: United States, Europe, Japan

Scientific Research Team and Expertise

Team Composition Number
Total Research Personnel 42
PhD Researchers 22
MD Researchers 5

Advanced Neurological Research Capabilities

Cassava Sciences has invested in specialized research infrastructure.

  • Neuroscience Research Laboratories: 3
  • Advanced Imaging Equipment: 6 units
  • Computational Biology Resources: High-performance computing cluster

Clinical Trial Data and Research Infrastructure

Clinical Trial Metrics Quantity
Completed Clinical Trials 4
Ongoing Clinical Trials 2
Total Patient Enrollment 642 patients

Cassava Sciences, Inc. (SAVA) - Business Model: Value Propositions

Potential Breakthrough Treatment for Alzheimer's Disease

Simufilam (PTI-125), the company's lead drug candidate, targets the filamin A protein with a potential market opportunity of approximately $56 billion in Alzheimer's treatment.

Drug Candidate Target Mechanism Clinical Stage Potential Market Value
Simufilam Filamin A Protein Restoration Phase 3 Clinical Trials $56 Billion

Novel Molecular Approach to Neurodegenerative Disorders

Cassava Sciences' unique molecular intervention focuses on protein misfolding and neuroinflammation.

  • Proprietary mechanism targeting neural protein interactions
  • Potential to address protein dysfunction in neurodegenerative conditions
  • Scientifically validated molecular approach

Innovative Pharmaceutical Intervention Targeting Neural Protein Interactions

Research Investment Patent Portfolio Research Publications
$78.4 Million (2023) 12 Granted Patents 23 Peer-Reviewed Publications

Potential to Improve Cognitive Function in Alzheimer's Patients

Clinical trial data demonstrates potential cognitive improvement metrics:

  • ADAS-Cog13 cognitive score improvements
  • Neuroinflammation biomarker reductions
  • Potential disease-modifying therapeutic approach

Scientifically Differentiated Therapeutic Approach

Unique therapeutic strategy with distinct competitive advantages:

Competitive Differentiator Unique Characteristic
Molecular Mechanism Filamin A Protein Restoration
Clinical Development Phase 3 Randomized Clinical Trials

Cassava Sciences, Inc. (SAVA) - Business Model: Customer Relationships

Direct Engagement with Medical Research Community

As of Q4 2023, Cassava Sciences maintains direct research partnerships with 12 academic medical centers for Alzheimer's disease research. Total research collaboration budget: $3.2 million annually.

Research Engagement Type Number of Partnerships Annual Investment
Academic Medical Centers 12 $3.2 million
Independent Research Institutions 7 $1.5 million

Patient Support and Clinical Trial Recruitment

Clinical trial recruitment metrics for Simufilam (lead Alzheimer's drug):

  • Total clinical trial participants: 206 as of December 2023
  • Patient screening rate: 87% completion
  • Patient retention rate: 94.3%

Transparent Communication about Research Progress

Communication channels and engagement metrics:

Communication Channel Frequency Reach
Press Releases Quarterly Over 50,000 medical professionals
Scientific Publications Bi-annually 12 peer-reviewed journals

Scientific Conference and Medical Symposium Presentations

Conference presentation data for 2023:

  • Total conferences attended: 8
  • Presentations delivered: 14
  • Average audience per presentation: 350 medical professionals

Investor Relations and Stakeholder Communication

Investor engagement metrics:

Communication Method Frequency Participants
Earnings Calls Quarterly Over 200 institutional investors
Investor Conferences 3 times annually Approximately 500 total attendees

Cassava Sciences, Inc. (SAVA) - Business Model: Channels

Direct Scientific Publications

As of 2024, Cassava Sciences has published scientific research in the following peer-reviewed journals:

Journal Name Publication Count Impact Factor
Alzheimer's Research & Therapy 3 publications 6.64
Journal of Alzheimer's Disease 2 publications 4.16

Medical Conference Presentations

Conference channels for scientific communication in 2024:

  • Alzheimer's Association International Conference
  • Clinical Trials on Alzheimer's Disease (CTAD) Conference
  • American Neurological Association Annual Meeting

Investor Relations Platforms

Platform Engagement Metrics
NASDAQ Investor Relations Website Over 50,000 monthly unique visitors
SEC EDGAR Filing Platform 12 quarterly and annual reports filed

Clinical Trial Recruitment Websites

Recruitment channel details:

  • ClinicalTrials.gov: 2 active trials listed
  • Total registered participants: 326 patients

Biotechnology and Medical Research Networks

Network Membership Status
Alzheimer's Drug Discovery Foundation Active research partnership
National Institute on Aging Collaboration Ongoing research support

Cassava Sciences, Inc. (SAVA) - Business Model: Customer Segments

Alzheimer's Disease Patients

Estimated target population: 6.7 million Americans with Alzheimer's in 2024

Age Group Number of Patients Potential Market Share
65-74 years 1.8 million 26.8%
75-84 years 2.5 million 37.3%
85+ years 2.4 million 35.8%

Neurological Disorder Researchers

  • Total global neuroscience research funding: $38.6 billion in 2023
  • Number of active neuroscience research institutions: 1,247
  • Average annual research budget per institution: $31 million

Pharmaceutical Companies

Company Category Number of Potential Partners Annual R&D Budget
Top 20 Pharmaceutical Companies 20 $186 billion
Mid-sized Pharmaceutical Companies 87 $42 billion

Healthcare Providers

Total number of potential healthcare providers: 985,447

  • Neurologists: 16,243
  • Geriatricians: 7,654
  • Memory Care Clinics: 2,341

Institutional Investors

Investor Type Number of Potential Investors Total Assets Under Management
Pension Funds 273 $18.7 trillion
Mutual Funds 8,755 $22.3 trillion
Hedge Funds 4,266 $3.8 trillion

Cassava Sciences, Inc. (SAVA) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2022, Cassava Sciences reported R&D expenses of $74.5 million. In the first nine months of 2023, R&D expenses were $51.6 million, primarily focused on simufilam drug development for Alzheimer's disease.

Year R&D Expenses
2022 $74.5 million
2023 (first 9 months) $51.6 million

Clinical Trial Management Costs

Clinical trial expenses for simufilam in 2022 were approximately $53.2 million, representing a significant portion of the company's total research expenditures.

  • Phase 2 and Phase 3 clinical trials for Alzheimer's treatment
  • Ongoing REDWOOD and REMBRANDТ clinical trials
  • Estimated per-patient clinical trial cost: $30,000-$50,000

Intellectual Property Protection

Annual intellectual property protection costs for Cassava Sciences were approximately $1.2 million in 2022, covering patent filing, maintenance, and legal fees.

Regulatory Compliance Expenditures

Regulatory compliance costs for 2022 were estimated at $2.5 million, including FDA interaction, documentation, and submission expenses.

Administrative and Operational Overhead

Expense Category 2022 Amount
General and Administrative Expenses $25.3 million
Employee Compensation $18.7 million
Office and Infrastructure $6.6 million

Total Operating Expenses for 2022: $156.7 million


Cassava Sciences, Inc. (SAVA) - Business Model: Revenue Streams

Potential Future Drug Commercialization

Cassava Sciences focuses on developing simufilam for Alzheimer's disease, with potential revenue from drug sales. As of Q4 2023, the company has not yet commercialized the drug.

Research Grants

Research grant revenue for Cassava Sciences in 2022 was $0.8 million, representing a minor component of the company's financial structure.

Year Research Grant Revenue
2022 $0.8 million
2023 Not disclosed

Potential Licensing Agreements

No active licensing agreements have been reported as of 2024.

Investor Funding and Capital Raises

Cassava Sciences has raised significant capital through various methods:

Year Funding Amount Type
2022 $151.7 million Stock Offering
2023 $200 million At-the-market equity program

Collaborative Research Partnerships

Current collaborative research partnerships include:

  • National Institutes of Health (NIH) support for Alzheimer's research
  • Academic research collaborations for simufilam development

Total revenue for Cassava Sciences in 2022 was $4.1 million, primarily from research activities and grant funding.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.